Sentences with phrase «allogeneic human»

In close collaboration with universities and physicians world - wide, our comprehensive investigational stem cell treatments employ well - targeted combinations of allogeneic human umbilical cord stem cells, autologous bone marrow stem cells, and autologous adipose stem cells for the diseases listed below.

Not exact matches

The present demonstration of T cell - mediated apoptosis of allogeneic corneal cells from CD4 KO mice is consistent with previous findings, which noted the presence of apoptotic keratocytes and corneal endothelial cells in rejected corneal allografts in humans and rats respectively (5, 32).

Human mesenchymal stem cells modulate allogeneic immune cell responses.

Suppression of allogeneic T - cell proliferation by human marrow stromal cells: implications in transplantation.

Allogeneic Mesenchymal Stem Cells Stimulate Cartilage Regeneration and Are Safe for Single - Stage Cartilage Repair in Humans upon Mixture with Recycled Autologous Chondrons.

• Patients must have adequate coagulation (international normalized ratio (INR) or prothrombin time (PT), partial thromboplastin time (PTT) ≤ 1.5 times ULN) • Adequate liver function (total bilirubin ≤ 1.5 times the ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN Exclusion Criteria: • Presence of active / uncontrolled central nervous system involvement • History of clinically significant cardiac disease; uncontrolled hypertension • Left ventricular ejection fraction (LVEF) < 45 % • Allogeneic stem cell transplant within 100 days before first dose of study drug • Known history of human immunodeficiency virus (HIV) infection • Chronic or active hepatitis B or C, requiring antiviral therapy • Evidence of history of bleeding disorder, dialysis, or coexisting cancer that is distinct in primary site or histology from the cancer evaluated in this study • Serious, uncontrolled infection • Unresolved chronic toxicity > grade 1 from prior therapy • Use of strong CYP3A4 inhibitors or strong inducers within 7 days prior to the start of study treatment and for the duration of the study

Patients receive one of two types of stem cell - based transplants: autologous, in which a patient donates and receives back his / her own stem cells; or allogeneic, in which bone marrow - derived stem cells come from a related or unrelated donor whose human leukocyte antigens (HLA) are genetically matched with those of a patient.